Catumaxomab
WikiDoc Resources for Catumaxomab |
Articles |
---|
Most recent articles on Catumaxomab Most cited articles on Catumaxomab |
Media |
Powerpoint slides on Catumaxomab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Catumaxomab at Clinical Trials.gov Clinical Trials on Catumaxomab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Catumaxomab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Catumaxomab Discussion groups on Catumaxomab Patient Handouts on Catumaxomab Directions to Hospitals Treating Catumaxomab Risk calculators and risk factors for Catumaxomab
|
Healthcare Provider Resources |
Causes & Risk Factors for Catumaxomab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Catumaxomab (removab®) is a rat-murine hybrid monoclonal antibody and which it's used to treat some cancers such as platinum-refractory ovarian cancer, malignant ascites, and gastric cancer. It binds to antigen CD3 and is also trifunctional. It is in clinical trials in the United States currently and is used in Europe.
It basically works by linking your T-lymphocytes with the cancer cells.